Financials
- Financial year
- 2025
- Total assets
- €10.6m
- Loss
- -€8.0m
- Solvency
- 47.8%
Total assets▼ 24.2%
Net result
20182025
ATB THERAPEUTICS
ActiveSummary
The annual accounts of ATB THERAPEUTICS for financial year 2025 show a net loss of 75% of total assets and of 61% of the equity at the start of that year. The 2025 annual accounts show equity of €5.1m and a net result of -€8.0m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 50% of 91 sector peers (NACE 21, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.5% (very low).
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21100Research and development on biotechnology NACE 72101
6th largest company by equity in Marche-en-Famenne, Manufacturing sector2 sites
Size
€10.6mtotal assets 2025
- Staff
- 17 FTE
- Equity
- €5.1m
- Loss
- -€8.0m
Structure
- Largest shareholder
- ORSA TECH · 14.19%
- Board
- 5 members
- CHITON ROCKSChair · permanent representative THROSBY Mark
Auditor: PwC Réviseurs d'Entreprise2025 accounts 11 days early8 of 14 deeds summarised
Why 54raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €8.0m, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 1.89, cash €1.9m, halvedEquity €5.1m (47.8% of total assets)Figures for financial year 2025 (filed 20-07-2026)Show the evidence
Checked score
Score 2025
54
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 28% of its sector peers (NACE 21, small)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency
73-27
equity 47.8% of total assets
Liquidity
47-53
short-term debt 49.7% · cash 17.5%
Profitability
0=
return on assets -75.2%
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 1.7%
12-2024: 1.7%● unchanged vs 11-2024
01-2025: 1.7%● unchanged vs 12-2024
02-2025: 1.7%● unchanged vs 01-2025
03-2025: 1.6%▼ -0.1 percentage points vs 02-2025
04-2025: 1.7%▲ +0.1 percentage points vs 03-2025
05-2025: 1.7%● unchanged vs 04-2025
06-2025: 1.9%▲ +0.2 percentage points vs 05-2025
07-2025: 2.1%▲ +0.2 percentage points vs 06-2025highest value
08-2025: 0.2%▼ -1.9 percentage points vs 07-2025lowest value
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.5%▲ +0.2 percentage points vs 07-2026
09-2026: 0.5%● unchanged vs 08-2026
10-2026: 0.5%● unchanged vs 09-2026
Credit of up to €270,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 1.89, compared with 15.01 in 2024, above the usual 1.5; short-term debt: 49.7% and cash: 17.5% of total assets), but 52.2% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 37% on solvency, 53% on liquidity, 14% on profitability and 9% on growth.
The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€8.0m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 20-07-2026, 11 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
11 days early
2024
17 days early
2023
16 days early
2022
31 days early
2021
30 days late
2020
117 days late
2019
28 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 6 days after the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 16 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
25-10-2026 today31-12-2026 year end31-07-2027 deadline
- Capital & shares · Amendment of…Correction · Capital increase ·…
- Annual accounts filedfinancial year 2025 · full…
- Capital & shares · Amendment of…Capital increase · Capital ·…
Key points
- Risk: 8 loss-making years in a rowloss financial year 2025 -€8.0m View
- Caution: Result fell in 2025from -€3.3m to -€8.0m ▼ 143% View
- Caution: Among the weakest 5% on net resultsector median €358,166 · 91 companies -€8.0m View
- Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View
By topic
Board & ownership
- Board
- 5 members
- Largest shareholder
- ORSA TECH · 14.19%
- Auditor
- PwC Réviseurs d'Entreprise
- CHITON ROCKSChair
- BRICHARD VincentDirector
- BROEKAERT WillemDirector
- DE KONING JohnDirector
- KLEINHANS KarinDirector
Timeline
- Events
- 19
- Since
- 2019
- Next accounts
- by 31-07-2027
- 31-12-2025Weakest financial year
- 14-07-2025Annual accounts filed
- 07-07-2025Capital & shares · Amendment of the…
Company details
- Sites
- 2
- Legal form
- Public limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
- Founded
- 06-07-2017
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 41
- Annual meeting
- Third Friday of June at 15:00
- Purpose
- “Alle activiteiten in verband met fundamenteel of toegepast onderzoek,alsook de…” (deed in Dutch)
Key facts about ATB THERAPEUTICS
- What is the company number of ATB THERAPEUTICS?
- 0677.980.015. In Belgium the VAT number is the company number with BE in front: BE 0677.980.015.
- Where is ATB THERAPEUTICS based?
- The registered office is at Aye, Rue de la Science 8, 6900 Marche-en-Famenne.Company details
- What does ATB THERAPEUTICS do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of ATB THERAPEUTICS?
- Public limited company (NV).
- When was ATB THERAPEUTICS founded?
- On 06-07-2017.
- Is ATB THERAPEUTICS still active?
- Yes, ATB THERAPEUTICS is an active enterprise in the KBO register.
- How many employees does ATB THERAPEUTICS have?
- On average 17 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of ATB THERAPEUTICS?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
- Is ATB THERAPEUTICS profitable?
- In financial year 2025, ATB THERAPEUTICS made a loss of €8.0m.
- Where can I find the annual accounts of ATB THERAPEUTICS?
- ATB THERAPEUTICS filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ATB THERAPEUTICS due?
- By 31-07-2027, for financial year 2026.Timeline
Companies related to ATB THERAPEUTICS
Shareholders
- ORSA TECH14.19%
- Vives Inter-University Fund4.97%
- ORSA FUND2.09%
- INVESTSUD INNOVATION0.9%
Comparable companies
- NAMSA BELGIUMDiest
- THYMOLUXMarche-en-Famenne
- UNIZIMACharleroi
- NeGIO TherapeuticsCharleroi
- Corden Pharma BrusselsElsene
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.